Global Market Study on Uterine Cancer Diagnostic Testing: Endometrium Carcinoma Segment to Lead in Terms of Value Through 2026


  • Rep Id : XPLREP3034
  • Published On : September, 2018
  • No. of Pages : 241
  • Category : In Vitro Diagnostics
  • Publisher : Persistence Market Research

XploreMR offers an eight year forecast on the global Uterine Cancer Diagnostic Testing market. The primary objective of the report is to offer updates and information related to market opportunities in the Uterine Cancer Diagnostic Testing market.

Report Description

In terms of revenue, the global Uterine Cancer Diagnostic Testing market is expected to register a CAGR of 7.8% during the forecast period, 2018–2026. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global Uterine Cancer Diagnostic Testing market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global Uterine Cancer Diagnostic Testing market are presented in the report.

The global market for Uterine Cancer Diagnostic Testing is expected to witness high growth rate in terms of value in high economic countries due to increase in incidence of uterine cancer cases and efficient healthcare infrastructure. Increase in healthcare expenditure and rising women geriatric population has also driven the market for Uterine Cancer Diagnostic Testing. Low and Middle economy countries like India and South Africa have a lower incidence rate for uterine cancer. The diagnosis rate is poor in these countries and thus, these countries witness low growth rate in terms of value for Uterine Cancer Diagnostic Testing market.

The report includes Uterine Cancer Diagnostic Test types like ultrasound scanning, biopsy procedures and blood tests. Ultrasound scanning has further been segmented into abdominal ultrasound scanning and transvaginal ultrasound scanning. Biopsy procedures include endometrial biopsy, hysteroscopy and dilation & curettage. Blood tests include a complete blood count test, also known as CBC and CA125 marker blood test.

However, the report does not include revenue generated by the imaging procedures like CT scans, MRI scans, X-Rays, PET scans, endoscopy procedures and other screening & treatment methods. Currency fluctuations and inflation are not considered while calculating the revenue of the Uterine Cancer Diagnostic Testing market.

Revenue from the Uterine Cancer Diagnostic Testing market in North America is expected to expand at a relatively higher CAGR due to growing awareness of women health and gynaecologic cancer. High incidence rates also contribute to the market for Uterine Cancer Diagnostic Testing in the region. To understand and assess the opportunities in this market, the report offers the market forecast on the basis of segment type classified into the cancer type, diagnostic test type, end users and regions. The report provides analysis of the global Uterine Cancer Diagnostic Testing market in terms of market value (US$ Mn).

The global Uterine Cancer Diagnostic Testing market is segmented on the basis of cancer type into:

  • Endometrial Carcinoma
  • Uterine Sarcoma

The report begins with the market definition of Uterine Cancer Diagnostic Testing, followed by definitions of different cancer and diagnostic test types. The market dynamics section includes XploreMR’s analysis on key trends, drivers, restraints, opportunities, macro-economic factors and reimbursement scenario influencing the growth of the global Uterine Cancer Diagnostic Testing market.

The report analyses the Uterine Cancer Diagnostic Testing market on the basis of diagnostic test type and end users and presents forecast in terms of value for the next 8 years. On the basis of diagnostic test type, the global Uterine Cancer Diagnostic Testing market is segmented into:

  • Ultrasound Scanning
    • Abdominal Ultrasound Scanning
    • Transvaginal Ultrasound Scanning
  • Biopsy Procedures
    • Endometrial Biopsy
    • Hysteroscopy
    • Dilation & Curettage
  • Blood Tests
    • Complete Blood Count
    • CA125 Marker Blood Test

On the basis of the end users, the global Uterine Cancer Diagnostic Testing market is segmented into:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Specialized Clinics
  • Diagnostic Laboratories
  • Others

Next, the report analyses the market on the basis of regions and presents forecast in terms of value for the next 8 years. On the basis of region, the global Uterine Cancer Diagnostic Testing market is segmented into:

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Poland
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific excluding China
    • India
    • China
    • Australia & New Zealand
    • ASEAN
    • Rest of Asia- Pacific excluding China
  • China
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global Uterine Cancer Diagnostic Testing market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by the Uterine Cancer Diagnostic Testing market. To understand the key segments in terms of their growth and performance in the global Uterine Cancer Diagnostic Testing market, XploreMR has developed a market attractiveness index. The resulting index will help identify the existing market opportunities in Uterine Cancer Diagnostic Testing market.

In the final section of the report, a ‘competitive landscape’ has been included to provide a dashboard view of the key companies operating in the global Uterine Cancer Diagnostic Testing market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the Uterine Cancer Diagnostic Testing market. However, this section also includes market strategies and SWOT analysis of the key players operating in the global Uterine Cancer Diagnostic Testing market.

Detailed profiles of Uterine Cancer Diagnostic Testing drug manufacturers are also included in the scope of the report to evaluate their long- and short-term strategies. Examples of some of the key players operating in the Uterine Cancer Diagnostic Testing market are Abbott, Roche Holdings AG, Siemens, Danaher and Biomerieux SA.

Uterine Cancer Diagnostic Testing Market